Cellules humaines à usage thérapeutique : état de la question()

por Guilhot, F.
Publicado 2020

High levels of interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNγ production in MAS

por Bracaglia, C, Marafon, D Pires, Caiello, I, de Graaf, K, Guilhot, F, Ferlin, W, Davì, S, Schulert, G, Ravelli, A, Grom, A, Nelson, R, de Min, C, De Benedetti, F
Publicado 2015

Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion

por Maurizot, A, Beressi, J-P, Manéglier, B, de la Marre, N H, Spentchian, M, Soury, P, Solvet-Sebire, P, Collet-Gaudillat, C, Baud, J-M, Livarek, B, Guilhot, F, Rousselot, P
Publicado 2014

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

por Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A., Hehlmann, R.
Publicado 2020